Novo Nordisk's (NOVOB.DK) shares dip about 16% due to the company lowering its full-year 2025 sales and operating profit outlook. Previously, investors had higher expectations for Novo Nordisk’s growth rates, but the updated guidance now forecasts sales growth in the 8–14% range for the year, which is below earlier projections (13-21%).
Today’s moves are largely due to weaker-than-expected Wegovy sales in the U.S. obesity market. The updated sales outlook specifically cites reduced growth expectations for Wegovy in the U.S., as well as slower-than-expected market expansion and stronger competition, particularly from Eli Lilly's rival drug Zepbound.
NOVOB shares are back at multi-year lows after cutting forecast. Source: xStation
Micron vs. Nvidia: Wall Street's New AI Darling Has Soared 18-Fold Since ChatGPT
Morgan Stanley delivers a blockbuster quarter. Record earnings spark Wall Street rally
BlackRock shares jump 5% after earnings 🔼 What did the Wall Street giant report?
Figure of the Day: What is next for July’s strongest currency? (15.07.2026)